https://charts.traderzeitung.de/phases/US6402683063 string(1398) "{"isin":"US6402683063","name":"Nektar Therapeutics","stock_id_xnas":7874507,"stock_id_xnys":null,"generated_at":"2026-09-01 08:43:00","days":[{"date":"2026-08-27","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":74.525,"close_at":"2026-08-27 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-28","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":72.71,"close_at":"2026-08-28 21:59:00","complete":true,"perf_pct":-2.4354},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-31","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":71.415,"close_at":"2026-08-31 21:59:00","complete":true,"perf_pct":-1.781},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"

Nektar Therapeutics Aktie News & Nachrichten

[WKN: A419UB | Symbol: NKTR]

Realtimekurs

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

07.07.2026 um 12 Uhr

Nektar Therapeutics

Nektar Therapeutics: Voller Fokus auf den Milliardenmarkt der Immunologie

Nektar Therapeutics verdient sein Geld nicht mit dem eigenen Medikamentenverkauf, sondern durch die...

21.04.2026 um 13 Uhr

TOP-5-Kursziele der Analysten am 21.04.26

Uber Technologies [US90353T1007] TD Cowen bestätigt Buy-Rating mit Kursziel 114 USD (47 % Kurspotenzial)...

16.03.2026 um 12 Uhr

TOP-5-Kursziele der Analysten am 16.03.26

Rocket Companies [US77311W1018] Keefe Bruyette nimmt Hochstufung von "Market Perform" auf "Outperform"...

11.02.2026 um 13 Uhr

TOP-5-Kursziele der Analysten am 11.02.26

Cloudflare [US18915M1071] TD Cowen bekräftigt Buy-Rating mit Kursziel 265 USD (28 % Kurspotenzial)...

Nektar Therapeutics Nachrichtenticker öffnen

MT Newswires 13.08.2026 22:32 Uhr

Nektar Therapeutics Q2-Verlust verringert sich, Umsatz sinkt

04:31 PM EDT, 13.08.2026 (MT Newswires) -- Nektar Therapeutics (NKTR) meldete am späten Donnerstag einen Verlust im Q2 von 1,23 $ je verwässerter Akti

MT Newswires 13.08.2026 22:25 Uhr

Earnings Flash (NKTR) Nektar Therapeutics meldet Verlust im Q2 von 1,23 USD je Aktie gegenüber FactSet-Schätzung von 1,97 USD Verlust

MT Newswires 13.08.2026 22:17 Uhr

-- Earnings Flash (NKTR) Nektar Therapeutics meldet Q2-Umsatz von 10,1 Mio. USD, verglichen mit FactSet-Schätzung von 10,4 Mio. USD

MT Newswires 22.07.2026 13:19 Uhr